Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.

CONCLUSIONS: TCZ is a therapeutic option for glucocorticoid-resistant orbitopathy, and should be considered in second line due to the cost of treatment or in first line in patients with contraindications to intravenous GC pulse therapy.
PMID: 32340849 [PubMed - as supplied by publisher]

Source: Annales d'Endocrinologie - April 9, 2020 Category: Endocrinology Authors: Ceballos-Macías José J, Rivera-Moscoso R, Flores-Real Jorge A, Vargas-Sánchez J, Ortega-Gutiérrez G, Madriz-Prado R, Velasco-Ramos PC, Muñoz-Monroy Omar E, Meneses-Pérez Anna C, Fernández-Morales Irma N, Hernández-Moreno A Tags: Ann Endocrinol (Paris) Source Type: research